Heron Therapeutics, Inc. Stock price

Equities

HRTX

US4277461020

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:56:12 2024-03-28 am EDT 5-day change 1st Jan Change
2.755 USD +0.55% Intraday chart for Heron Therapeutics, Inc. -9.84% +61.76%
Sales 2024 * 146M Sales 2025 * 176M Capitalization 412M
Net income 2024 * -32M Net income 2025 * -9M EV / Sales 2024 * 2.82 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.35 x
P/E ratio 2024 *
-12.8 x
P/E ratio 2025 *
-43.3 x
Employees 126
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.11%
More Fundamentals * Assessed data
Dynamic Chart
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup DJ
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Heron Therapeutics Shares Soar After Q4 Results Beat MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $4, Keeps Buy Rating MT
Transcript : Heron Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q4 Revenue $34.2M, vs. Street Est of $31.2M MT
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024 CI
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef DJ
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures MT
Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Boeing 737 Max 9 Grounding MT
Heron Therapeutics Unveils Deal to Expand Sales Network for Postoperative Pain Control Anesthetic; Shares Rise Premarket MT
Heron Therapeutics, Inc. Enters into Five-Year Distributor Partnership with Crosslink Life Sciences, LLC to Expand the Sales Network Supporting ZYNRELEF CI
More news
1 day+0.55%
1 week-9.84%
Current month+3.38%
1 month+1.85%
3 months+58.05%
6 months+183.51%
Current year+61.76%
More quotes
1 week
2.67
Extreme 2.67
3.08
1 month
2.30
Extreme 2.3
3.22
Current year
1.66
Extreme 1.66
3.22
1 year
0.50
Extreme 0.5
3.22
3 years
0.50
Extreme 0.5
18.99
5 years
0.50
Extreme 0.5
26.81
10 years
0.50
Extreme 0.5
42.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 23-02-20
Director of Finance/CFO 55 23-06-15
Chief Tech/Sci/R&D Officer 58 18-10-31
Members of the board TitleAgeSince
Chief Executive Officer 58 23-02-20
Director/Board Member 60 21-09-19
Director/Board Member 62 14-01-12
More insiders
Date Price Change Volume
24-03-28 2.75 +0.36% 296 925
24-03-27 2.74 0.00% 1,225,830
24-03-26 2.74 -7.12% 1,978,408
24-03-25 2.95 -0.67% 1,310,142
24-03-22 2.97 -2.62% 1,263,904

Delayed Quote Nasdaq, March 28, 2024 at 11:38 am EDT

More quotes
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.74 USD
Average target price
7 USD
Spread / Average Target
+155.47%
Consensus
  1. Stock
  2. Equities
  3. Stock Heron Therapeutics, Inc. - Nasdaq